GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » Net Income

Zylox-Tonbridge Medical Technology Co (HKSE:02190) Net Income : HK$107.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Zylox-Tonbridge Medical Technology Co's Net Income for the six months ended in Jun. 2024 was HK$74.1 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$107.7 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Zylox-Tonbridge Medical Technology Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.23.


Zylox-Tonbridge Medical Technology Co Net Income Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co Net Income Chart

Zylox-Tonbridge Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial -119.10 -244.51 -126.81 -86.12 107.04

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -98.33 -38.85 -47.27 74.14 33.52

Zylox-Tonbridge Medical Technology Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Zylox-Tonbridge Medical Technology Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-86.118+0+0+0
=-86.1

Zylox-Tonbridge Medical Technology Co's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=74.136+0+0+0
=74.1

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$107.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zylox-Tonbridge Medical Technology Co  (HKSE:02190) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Zylox-Tonbridge Medical Technology Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Zylox-Tonbridge Medical Technology Co Net Income Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zylox-Tonbridge Medical Technology Co Business Description

Traded in Other Exchanges
Address
270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).
Executives
Wang Stephen Hui 2201 Interest of corporation controlled by you
Hang Zhou Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Wea Enterprises, Llc 2401 A concert party to an agreement to buy shares
Zhong Shengping Sam 2401 A concert party to an agreement to buy shares
Zhao Jonathon Zhong 2501 Other
Wei Na 2501 Other
Li Zheng 2501 Other
Schroders Plc 2102 Investment manager
Ourea Biotech Hk Limited 2501 Other
Highlight Medical Limited 2501 Other
Five Investment Limited 2501 Other

Zylox-Tonbridge Medical Technology Co Headlines

No Headlines